BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

SimonMed Imaging partners with Korea's Lunit to bring new era of AI-powered breast cancer detection

April 24, 2025 | News

A major leap forward in patient health and the future of mammography



SimonMed Imaging, one of the largest and most advanced outpatient medical imaging providers in the United States, has announced partnership with South Korea-based Lunit, a global leader in artificial intelligence (AI)-driven cancer diagnostics and therapeutics, to bring a new era of AI-powered breast cancer detection to patients across the country. The partnership marks a major milestone in SimonMed's mission to save lives through early detection.

SimonMed has selected Lunit INSIGHT DBT, in combination with Volpara Analytics, as the most advanced AI solution for breast cancer screening after an extensive evaluation of technologies on the market.

This best-in-class software will now power SimonMed's Personalised Breast Cancer Detection (PBCD) service, designed to provide every patient with a precise, highly personalized, and data-driven screening experience.

Lunit INSIGHT DBT is trained on millions of images and engineered to detect even the most subtle signs of breast cancer, improving both sensitivity and specificity. Integrated into SimonMed's national network of over 170 accredited centers and supported by more than 200 subspecialty-trained radiologists, this AI solution helps ensure earlier detection, faster turnaround times, and actionable insights for patients.